Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Frank K. Bedu-Addo
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Beta
- 1.45
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -46.02
Financials
Net Income
$-9.75MEBITDA
$-6.50MFree Cash Flow
$-2.79MEPS (diluted)
$-0.18Shares Outstanding (diluted)
55.66M+3751.9%Operating Expenses
$6.50MCash & Debt
$5.60MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-34.50M | $-0.74 |
| 2024 | $0.00 | $-37.61M | $-1.03 |
| 2023 | $0.00 | $-42.94M | $-1.39 |
| 2022 | $0.00 | $-40.85M | $-1.43 |
| 2021 | $0.00 | $-16.92M | $-0.66 |
| 2020 | $0.00 | $-14.85M | $-0.89 |
| 2019 | $0.00 | $-7.00M | $-1.44 |
| 2018 | $0.00 | $-40.87M | $-26.16 |
| 2017 | $0.00 | $-50.86M | $-33.47 |
| 2016 | $0.00 | $-38.82M | $-26.90 |
| 2015 | $0.00 | $-28.08M | $-20.02 |
| 2014 | $0.00 | $-12.20M | $-16.15 |
| 2013 | $0.00 | $-6.88M | $-9.11 |
| 2012 | $0.00 | $-4.70M | $-6.22 |
Valuation
PDSBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90Social Signal Score
Mentions (1)
- Newsdefenseworld.net·9d ago·Negative
PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Update PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totaling 6,406,521 shares, an increase of 172.7% from the August 31st total of 2,349,694 shares. Based on an average daily trading volume, of 97,840,279 shares, the days-to-cover
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.11 per share
Typical surprise +13.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.18 vs $-0.13miss
- Wed, May 13$-0.13 vs $-0.15beat
- Mon, Mar 30$-0.14 vs $-0.20beat
- Thu, Nov 13$-0.19 vs $-0.21beat
- Wed, Aug 13$-0.21 vs $-0.24beat
- Wed, May 14$-0.21 vs $-0.25beat
Estimates and results for PDSB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PDSB officers and directors.
- Bought
- $223k
- Sold
- —
9 trades
0 trades
- Freitag Gregory Genebought
- Freitag Gregory Genebought
- Glover Stephen C.bought
- Glover Stephen C.bought
- Hill Matthew Cbought
- Hill Matthew Cbought
- Hill Matthew Cbought
- Hill Matthew Cbought
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PDSB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.